HLB bioStepLtd (A278650) Stock Overview
Provides various test services in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
A278650 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
HLB bioStep Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,425.00 |
| 52 Week High | ₩2,020.00 |
| 52 Week Low | ₩1,086.00 |
| Beta | -0.044 |
| 1 Month Change | 17.09% |
| 3 Month Change | -1.38% |
| 1 Year Change | -12.68% |
| 3 Year Change | -71.44% |
| 5 Year Change | -52.68% |
| Change since IPO | -64.86% |
Recent News & Updates
Is HLB bioStepLtd (KOSDAQ:278650) A Risky Investment?
Jan 23
HLB bioStep Co.,Ltd.'s (KOSDAQ:278650) Business And Shares Still Trailing The Industry
Nov 04Recent updates
Is HLB bioStepLtd (KOSDAQ:278650) A Risky Investment?
Jan 23HLB bioStep Co.,Ltd.'s (KOSDAQ:278650) Business And Shares Still Trailing The Industry
Nov 04Revenues Working Against HLB bioStep Co.,Ltd.'s (KOSDAQ:278650) Share Price Following 29% Dive
Mar 21Unpleasant Surprises Could Be In Store For HLB bioStep Co.,Ltd.'s (KOSDAQ:278650) Shares
Jan 03Does HLB bioStepLtd (KOSDAQ:278650) Have A Healthy Balance Sheet?
Oct 21Is HLB bioStepLtd (KOSDAQ:278650) Using Debt Sensibly?
Jul 17HLB bioStep Co.,Ltd. (KOSDAQ:278650) Shares May Have Slumped 33% But Getting In Cheap Is Still Unlikely
May 22Subdued Growth No Barrier To HLB bioStep Co.,Ltd. (KOSDAQ:278650) With Shares Advancing 29%
Mar 29Here's Why HLB bioStepLtd (KOSDAQ:278650) Has A Meaningful Debt Burden
Feb 28With EPS Growth And More, KNOTUSLtd (KOSDAQ:278650) Is Interesting
Mar 17What Kind Of Investors Own Most Of KNOTUS Co.,Ltd (KOSDAQ:278650)?
Feb 24Is KNOTUSLtd (KOSDAQ:278650) Using Too Much Debt?
Feb 03
Investors Who Bought KNOTUSLtd (KOSDAQ:278650) Shares A Year Ago Are Now Up 26%
Jan 13Should We Be Delighted With KNOTUS Co.,Ltd's (KOSDAQ:278650) ROE Of 15%?
Dec 23Is Now The Time To Put KNOTUSLtd (KOSDAQ:278650) On Your Watchlist?
Dec 02Shareholder Returns
| A278650 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 14.6% | -2.0% | 8.4% |
| 1Y | -12.7% | 5.1% | 130.1% |
Return vs Industry: A278650 underperformed the KR Life Sciences industry which returned 5.1% over the past year.
Return vs Market: A278650 underperformed the KR Market which returned 130.1% over the past year.
Price Volatility
| A278650 volatility | |
|---|---|
| A278650 Average Weekly Movement | 7.8% |
| Life Sciences Industry Average Movement | 10.1% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in KR Market | 16.2% |
| 10% least volatile stocks in KR Market | 4.6% |
Stable Share Price: A278650 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A278650's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 150 | n/a | hlbbiostep.com |
HLB bioStep Co.,Ltd. provides various test services in South Korea. It offers non clinical CRO services for cancer, bone and brain disease, endocrineand metabolic and eye disease, liver and circulatory system disease, dental and gastrointestinal disease, hair growth, kidney and respiratory disease, painmodel, and skin disease.
HLB bioStep Co.,Ltd. Fundamentals Summary
| A278650 fundamental statistics | |
|---|---|
| Market cap | ₩115.43b |
| Earnings (TTM) | -₩18.96b |
| Revenue (TTM) | ₩74.05b |
Is A278650 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A278650 income statement (TTM) | |
|---|---|
| Revenue | ₩74.05b |
| Cost of Revenue | ₩18.14b |
| Gross Profit | ₩55.91b |
| Other Expenses | ₩74.87b |
| Earnings | -₩18.96b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -224.06 |
| Gross Margin | 75.50% |
| Net Profit Margin | -25.61% |
| Debt/Equity Ratio | 29.6% |
How did A278650 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/15 12:02 |
| End of Day Share Price | 2026/04/15 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HLB bioStep Co.,Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joong So | SK Securities Co., Ltd. |